Latest round: IPO. Peter Blume-Jensen is the President and CEO of Acrivon Therapeutics, a clinical-stage oncology company focused on precision medicine.
Peter Blume-Jensen is the President and CEO of Acrivon Therapeutics, a clinical-stage oncology company focused on precision medicine. He co-founded the company and has led it through an oversubscribed Series B round and a subsequent IPO. He emphasizes the company's clinical-stage asset and its differentiated patient selection platform.
Full founder directory · Investor directory · Company funding database · Fundraising library